Imagine Pharma Unveils First Generation Insulin-Producing DT1 Islet Cell Population at American Transplant Congress | New

Presentation of the research, “Generation of insulin-producing cells from pancreatic tissue with long-standing type 1 diabetes” will take place today at 4:30 p.m. EDT

PITTSBURGH and BOSTON, June 6, 2022 /PRNewswire/ — Imagine Pharmaa biotechnology company focused on developing its novel polypeptide (IMG-1) across three distinct platforms: oral delivery, therapeutics and regenerative medicine, will present its discovery of diabetes-activated islet progenitor cells from type 1 (T1D AIPCs) during its oral presentation today at the American Congress of Transplantation being detained in Boston. This breakthrough in the industry introduces an essential element for the potential treatment of T1D in the context of autologous cell transplantation. Type 1 diabetes affects approximately 1.6 million people in the United States and over 20 million people worldwide.

T1D AIPCs are a novel cell population generated and propagated from isolated human T1D islets or pancreatic biopsies using a simple culture protocol. The results show that DT1 AIPCs secrete insulin in response to secretagogues. The research generated T1D AIPCs from 8 different tissue/cell preparations from patients aged 27-58 years with long-standing type 1 diabetes (more than 15 years). Notably, T1D AIPCs were generated in sufficient quantities to support autologous transplantation.

“We are very pleased to share our news with the transplant and diabetes communities, and are honored to present our findings today at the American Transplant Congress,” said Ngoc Thai, MD, PhD, Founder of Imagine Pharma, co-CEO and CMO. “We envision that our novel population of AIPC T1D cells has enormous potential for the treatment and cure of type 1 diabetes via autologous cell transplantation.

Presentation details

Imagine Pharma will also have a poster presentation, “Characterization of Proliferating Activated Islet Cells (AIPC) During Pseudo-Islet Maturation,” which details Imagine Pharma’s progress in islet cell regeneration and characterization. The poster will be presented on Tuesday, June 7eat 7:00 p.m. EDT at Hynes Halls C&D.

About Imagine Pharma

Imagine Pharma is a biotechnology company focused on the development of its IMG-1 polypeptide. Research and development efforts have led to the development of three distinct platforms for oral delivery, therapeutics and regenerative medicine, each with first-class programs that address multiple disease states in large, underserved markets. Imagine Pharma was founded in 2016 in Pittsburgh, Pennsylvania. For more information visit: www.imaginepharma.com

About the American Congress of Transplantation

The American Transplant Congress is designed for physicians, surgeons, scientists, nurses, organ procurement personnel, pharmacists, and other transplant professionals interested in the clinical and research aspects of transplantation of solid organs and tissues. The meeting provides the most recent information in the field of transplantation science. More information is available HERE.

Show original content:https://www.prnewswire.com/news-releases/imagine-pharma-unveils-industry-first-generation-of-insulin-producer-t1d-islet-cell-population-at-the-american-transplant-congress- 301561411.html

SOURCEImagine Pharma